Vitiligo: Current Therapies and Future Treatments

被引:0
|
作者
Seneschal, Julien [1 ,2 ,3 ]
Boniface, Katia [2 ]
机构
[1] CHU Bordeaux, Hop St Andre, Dept Dermatol, Bordeaux, France
[2] Univ Bordeaux, CNRS, UMR 5164, Immuno ConcEpT, Bordeaux, France
[3] Bordeaux Univ, CNRS, UMR 5164, ImmunoConcept, F-33000 Bordeaux, France
来源
关键词
vitiligo; management; treatment; 0.1-PERCENT TACROLIMUS; DOUBLE-BLIND; PHOTOTHERAPY; HEAT-SHOCK-PROTEIN-70; DEPIGMENTATION; COMBINATION; EFFICACY; LASER;
D O I
10.5826/dpc.1304S2a313S
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficacy in many cases. First, it is important to identify patients in the active phase of the disease because treatment should start as soon as possible to halt its progression. For pa-tients with a stable disease, the treatment strategy is now well-stratified and is based on a combination of phototherapy (natural or in a cabin) and topical immunomodulatory agents. Surgical treatments are useful for localized and stable vitiligo, as well as for segmental vitiligo. Depigmentation remains indicated in very extensive forms. The recent approval of topical ruxolitinib cream in both the US and Europe brings new approaches for the management of vitiligo and paves the way for the development of new topical or oral targeted drugs.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Current and emerging treatments for vitiligo
    Rodrigues, Michelle
    Ezzedine, Khaled
    Hamzavi, Iltefat
    Pandya, Amit G.
    Harris, John E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 17 - 29
  • [2] Treatments in NMO: current algorithms, future therapies and trial designs
    Palace, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 6 - 7
  • [3] Safety of the current drug treatments for vitiligo
    Lotti, Torello
    Agarwal, Komal
    Podder, Indrashis
    Satolli, Francesca
    Kassir, Martin
    Schwartz, Robert A.
    Wollina, Uwe
    Grabbe, Stephan
    Navarini, Alexander A.
    Mueller, Simon M.
    Goldust, Mohamad
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 499 - 511
  • [4] Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments
    Ghashghaei, Shahriar
    Abbaszadeh, Mahkameh
    Karimi, Shahedeh
    Ataie-Fashtami, Leila
    Bajouri, Amir
    Vosough, Massoud
    [J]. CELL JOURNAL, 2023, 25 (03) : 143 - 157
  • [5] Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
    Guerra, Liliana
    Dellambra, Elena
    Brescia, Serena
    Raskovic, Desanka
    [J]. CURRENT DRUG METABOLISM, 2010, 11 (05) : 451 - 467
  • [6] Patients' perspective on current treatments and demand for novel treatments in vitiligo
    Narayan, V. S.
    Uitentuis, S. E.
    Luiten, R. M.
    Bekkenk, M. W.
    Wolkerstorfer, A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (03) : 744 - 748
  • [7] Review of current clinical studies of vitiligo treatments
    Korobko, Igor V.
    [J]. DERMATOLOGIC THERAPY, 2012, 25 : S17 - S27
  • [8] Current Status of Cell-Based Therapies for Vitiligo
    Domaszewska-Szostek, Anna
    Polak, Agnieszka
    Slupecka-Ziemilska, Monika
    Krzyzanowska, Marta
    Puzianowska-Kuznicka, Monika
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [9] Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
    Ray Chaudhuri K.
    Qamar M.A.
    Rajah T.
    Loehrer P.
    Sauerbier A.
    Odin P.
    Jenner P.
    [J]. npj Parkinson's Disease, 2 (1)
  • [10] Vitiligo: an update on current pharmacotherapy and future directions
    Colucci, Roberta
    Lotti, Torello
    Moretti, Silvia
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (13) : 1885 - 1899